Intuitive Surgical (ISRG)
(Delayed Data from NSDQ)
$507.42 USD
+1.08 (0.21%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $507.62 +0.20 (0.04%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$507.42 USD
+1.08 (0.21%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $507.62 +0.20 (0.04%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
Zacks News
Here's Why You Should Buy Intuitive Surgical (ISRG) Now
by Zacks Equity Research
A solid outlook for 2018 and strength in robotics make Intuitive Surgical (ISRG) a promising investment pick.
Has Intuitive Surgical (ISRG) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ISRG) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Intuitive Surgical, HCA Healthcare, Exelon, 3M and Micron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intuitive Surgical, HCA Healthcare, Exelon, 3M and Micron
Intuitive Surgical (ISRG) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Intuitive Surgical (ISRG) closed at $512.25, marking a -0.66% move from the previous day.
Top Research Reports for Intuitive Surgical, HCA Healthcare & Exelon
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Intuitive Surgical (ISRG), HCA Healthcare (HCA) and Exelon (EXC).
Top Analyst Reports for Adobe, Morgan Stanley & Enbridge
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Adobe (ADBE), Morgan Stanley (MS) and Enbridge (ENB).
Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ISRG) Outperforming Other Medical Stocks This Year?
Intuitive Surgical (ISRG) Stock Moves -0.18%: What You Should Know
by Zacks Equity Research
Intuitive Surgical (ISRG) closed at $520.97 in the latest trading session, marking a -0.18% move from the prior day.
RTI Surgical Gains From HealthPartners' Nod for SI Surgery
by Zacks Equity Research
RTI Surgical's (RTIX) minimally invasive SImmetry System sees lucrative market prospects for the stock's growth.
Medtronic's Deal With Nutrino Health to Boost Diabetes Arm
by Zacks Equity Research
Bringing Nutrino under Medtronic's (MDT) Diabetes Group will help the acquirer speed up its growth in the same business.
Medtronic Gets Health Canada License for Visualase System
by Zacks Equity Research
Medtronic (MDT) adopts initiatives to boost top-line contributions from the Brain Therapies arm.
Here's Why You Should Buy Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Strength in the surgical platform and an upbeat view for 2018 make Intuitive Surgical (ISRG) a promising pick.
Insulet's (PODD) Omnipod DASH System Now ISO 27001 Certified
by Zacks Equity Research
Insulet (PODD) is now the only insulin pump company to be awarded with both the ISO 27001 and the DTSec Cybersecurity Standard for Connected Diabetes Device Security certifications.
Intuitive Surgical (ISRG) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Intuitive Surgical (ISRG) closed at $485.24 in the latest trading session, marking a +0.53% move from the prior day.
Intuitive Surgical (ISRG) Down 0.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Intuitive Surgical (ISRG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ISRG) Outperforming Other Medical Stocks This Year?
Intuitive Surgical (ISRG) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Intuitive Surgical (ISRG) closed at $498.64 in the latest trading session, marking a -0.95% move from the prior day.
GNC Holdings (GNC) Q3 Earnings Miss on Soft U.S. Retail
by Zacks Equity Research
GNC Holdings (GNC) discourages with sluggish domestic retail comps. However, it delivers a strong performance in e-commerce business as well as at International segment.
Looking for a Growth Stock? Why It is Time to Focus on Intuitive Surgical (ISRG)
by Zacks Equity Research
Intuitive Surgical (ISRG) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Phibro Animal (PAHC) Q1 Earnings Lag Estimates, Sales Up Y/Y
by Zacks Equity Research
Within Animal Health business of Phirbo Animal (PAHC), reduced selling prices across certain countries partially offset its international volume growth.
OPKO Health (OPK) Incurs Loss in Q3, Lags Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) gains from robust demand for its flagship RAYALDEE in Q3; adjusted gross margin remains pressed.
Haemonetics (HAE) Earnings & Revenues Beat Estimates in Q2
by Zacks Equity Research
Haemonetics' (HAE) year-over-year growth in Q2 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.
athenahealth (ATHN) Q3 Earnings Beat, Bookings Down Y/Y
by Zacks Equity Research
athenahealth's (ATHN) Business and Services unit sees a strong Q3; 2018 guidance maintained.
DexCom (DXCM) Beats Q3 Earnings Estimates, Raises '18 View
by Zacks Equity Research
Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q3 results.
Surmodics' (SRDX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) sees solid segmental performance in fiscal Q4; gains from alliance with Abbott.